Hunjadi, M., Lamina, C., Kahler, P. et al. HDL cholesterol efflux capacity is inversely associated with subclinical cardiovascular risk markers in young adults: The cardiovascular risk in Young Finns study. Sci Rep 10, 19223 (2020). https://doi.org/10.1038/s41598-020-76146-7
HDL cholesterol efflux capacity is inversely associated with subclinical cardiovascular risk markers in young adults : the cardiovascular risk in Young Finns study
|Author:||Hunjadi, Monika1; Lamina, Claudia2; Kahler, Patrick1;|
1Department of Internal Medicine I, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria
2Division of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria
3Department of Medicine, University of Turku and Division of Medicine, Turku University Hospital, Turku, Finland
4Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
5Department of Clinical Physiology, Tampere University Hospital and Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
6Department of Microbiology and Immunology, Faculty of Medicine and Health Technology, Tampere University and Pirkanmaa Hospital District, Tampere, Finland
7Vaasa Central Hospital, Vaasa, Finland
8Department of Clinical Physiology and Nuclear Medicine, Kuopio, University Hospital and University of Eastern Finland, Kuopio, Finland
9Department of Pediatric Cardiology, Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
10Department of Pediatrics, Oulu University Hospital, PEDEGO Research Unit and MRC Oulu, University of Oulu, Oulu, Finland
11Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland
|Online Access:||PDF Full Text (PDF, 1.5 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe202102084052
|Publish Date:|| 2021-02-08
The atherogenic process begins already in childhood and progresses to symptomatic condition with age. We investigated the association of cholesterol efflux capacity (CEC) and vascular markers of subclinical atherosclerosis in healthy, young adults. CEC was determined in 2282 participants of the Young Finns study using cAMP treated ³H-cholesterol-labeled J774 cells. The CEC was correlated to baseline and 6-year follow-up data of cardiovascular risk factors and ultrasound measurements of arterial structure and function. CEC was higher in women, correlated with total cholesterol, HDL-C, and apolipoprotein A-I, but not with LDL-C or apolipoprotein B. Compared to the lowest CEC quartile, the highest CEC quartile was significantly associated with high CRP levels and inversely associated with adiponectin. At baseline, high CEC was associated with decreased flow-mediated dilation (FMD) and carotid artery distensibility, as well as an increased Young’s modulus of elasticity, indicating adverse changes in arterial structure, and function. The association reversed with follow-up FMD data, indicating the interaction of preclinical parameters over time. A higher CEC was directly associated with a lower risk of subclinical atherosclerosis at follow-up. In young and healthy subjects, CEC was associated with important lipid risk parameters at baseline, as in older patients and CAD patients, but inversely with early risk markers for subclinical atherosclerosis.
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3121 General medicine, internal medicine and other clinical medicine
The Young Finns Study has been financially supported by the Academy of Finland: grants 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), 41071 (Skidi) and 322098; the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research; Finnish Cultural Foundation; The Sigrid Juselius Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; EU Horizon 2020 (grant 755320 for TAXINOMISIS); European Research Council (grant 742927 for MULTIEPIGEN project); and Tampere University Hospital Supporting Foundation. In addition, this work has been funded by the Austrian Science Foundation FWF, Vienna, Austria (P27116-B23 to AR) and the Austrian Atherosclersosis Society (AAS).
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.